News Release 

Andrei Gudkov to present at the 6th Aging Research, Drug Discovery, and AI Forum in Basel

InSilico Medicine

IMAGE

IMAGE: Andrei Gudkov, PhD., D.Sci., Professor of Oncology at the Roswell Park Comprehensive Cancer Center, to present "Retrobiome as a driver of intrinsic DNA damage in aging " at the 6th Ageing... view more 

Credit: Insilico Medicine

Friday, August 16, 2019 - Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Andrei Gudkov, PhD., D.Sci., Professor of Oncology at the Roswell Park Comprehensive Cancer Center, at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019 in Basel, Switzerland.

"DNA damage in somatic cells accompanied with sterile chronic inflammation are common hallmarks of aging. Epigenetic derepression of endogenous retroelements that occupy nearly half of mammalian genome contributes to both. Approaches to targeting the 'retrobiome' for anti-aging treatment will be discussed," said Andrei Gudkov, PhD., D.Sci., Professor of Oncology at the Roswell Park Comprehensive Cancer Center, Scientific Founder of Genome Protection, Inc..

"I am very excited about welcoming Professor Andrei Gudkov to Basel. Professor Gudkov has dedicated much of his scientific life to understanding cancer and how the transcription factor p53 impacts tumor as well as normal cellular homeostasis. He has been a leader in this field for decades and I am therefore very honored that Professor Gudkov is joining our meeting," said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

"Over the last 5 years, the "Ageing & Drug Discovery" and "AI for Healthcare" forums have been leading events at Basel Life, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled "the 6th Ageing, AI and Drug Discovery Forum" to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet," said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.

"The 6th annual Ageing Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in ageing and longevity research covering the theory, applications and convergence of these three exciting areas," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.

The 6th Ageing Research, Drug Discovery, and AI Forum Basel will bring together leaders in the ageing, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of ageing and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: ageing. The Forum will be held in Basel, Switzerland, September 10-12, 2019.

###

For further information, images or interviews, please contact: Ola Popova ola@pharma.ai

About Andrei Gudkov, Ph.D

Andrei Gudkov, Ph.D., Dr.Sci., Professor of Oncology, Sr. Vice President for Research Technology and Innovation and Chair of the Department of Cell Stress Biology of Roswell Park Comprehensive Cancer Center (Buffalo, NY). He graduated from Moscow State University and received his academic degrees working at the National Cancer Center in Moscow, former USSR. In 1990 he moved to the US to join Department of Genetics at the University of Illinois at Chicago. In 2001 he became Chair of the Department of Molecular Genetics at Cleveland Clinic and Professor of Biochemistry of Case Western Reserve University in Cleveland, OH. In 2007 he moved his research operations to Buffalo, New York, to take his current position at Roswell Park. He founded biotech companies Cleveland Biolabs, Incuron, Everon Biosciences, Oncotartis and Genome Protection that develop anticancer, antiaging and biodefense drugs. His interests have spanned through multiple areas of biomedical research including endogenous viruses, functional genomics, drug discovery, p53, inflammation, radiation biology and aging.

About Roswell Park Comprehensive Cancer Center

Founded in 1898 as the nation's first cancer center, Roswell Park set the standard for today's multidisciplinary approach to the highest quality cancer care. The main goal is to eliminate cancer's grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. This will be achieved by pioneering promising therapeutic breakthroughs, using them to zero in on the most effective treatment for each patient, and committing in every situation, and every decision we face, big and small, to choose our words and actions based solely on the needs of each patient, and nothing more.

Official website: https://www.roswellpark.org/

About Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and ageing research.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Ageing Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Official website: http://insilico.com

About the Scheibye-Knudsen Laboratory

The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of ageing is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.

In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of ageing in model organisms. These findings suggest that normal ageing and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

Laboratory website: http://scheibye-knudsen.com/

About the University of Copenhagen

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.

University Website: http://introduction.ku.dk/presentation/

About Basel Life 2019

Ageing Research for Drug Discovery Forum description

In this symposium, leaders in the ageing, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of ageing and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: ageing. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet. Conference Official Website: https://www.basellife.org/2019.html

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.